TD Cowen named Alpine Immune Sciences a best idea for 2024 while keeping an Outperform rating on the shares. The analyst says povetacicept’s 24-week UPCR reduction at 80 mg is higher than any in the class, and the possibility for improvement at 240 mg in the first half of 2024 is “underappreciated as it could solidify its leading profile.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALPN: